University of Kansas Cancer Center Post San Antonio Review

 

2021
14:39

University of Kansas Cancer Center Post San Antonio Review

What's New in HER2+ MBC Targeted Therapy: Efficacy Analysis of Oral HER2-TKIs Tucatinib & Neratinib

FEATURING Heather McArthur
  • 373 views
  • March 5, 2021
  • 1
16:19

University of Kansas Cancer Center Post San Antonio Review

2021 Changing Treatment Paradigms for HER2+ mBC: Expert Efficacy Analysis of HER2 Targeted Therapy

FEATURING Heather McArthur
  • 190 views
  • March 5, 2021
  • 1
14:55

University of Kansas Cancer Center Post San Antonio Review

50 y/o Premenopausal Woman With T2N1mic BC: Would You Order Gene Expression Test to Aid Adjuvant Chemo Decision? Should You Recommend Adjuvant Chemo if Oncotype Dx Shows Score of 10?

FEATURING Priyanka Sharma, Sara Tolaney, Ingrid Mayer, Qamar Khan, Justin Balko
  • 61 views
  • February 28, 2021
14:05

University of Kansas Cancer Center Post San Antonio Review

Challenging Cases of BC: What Should Be the Next Line of Therapy for a Woman With HR+ mBC Who Received 1L ET + CDK4/6i? Should You Extend ET Beyond 5 Yrs for T2N0 HR+ Grade II IDC?

FEATURING Priyanka Sharma, Sara Tolaney, Ingrid Mayer, Qamar Khan, Justin Balko
  • 311 views
  • February 28, 2021
  • 1
12:04

University of Kansas Cancer Center Post San Antonio Review

48 y/o PALB2 Mutation Carrier With T2N0 ER/PR+, HER2- BC: How to Counsel This Patient? What Treatment to Recommend in the Metastatic Setting?

FEATURING Priyanka Sharma, Jennifer Klemp, Heather McArthur, Susan Domchek
  • 264 views
  • February 28, 2021
  • 1
08:29

University of Kansas Cancer Center Post San Antonio Review

42 y/o With cT2N Grade III TNBC: Does Inclusion of CPIs & Carboplatin in the Neoadjuvant Regimen Influence Recommendation for Adjuvant Capecitabine? What About Adjuvant Pembro? How to Counsel Regarding ctDNA Monitoring?

FEATURING Priyanka Sharma, Jennifer Klemp, Heather McArthur, Susan Domchek
  • 154 views
  • February 28, 2021
07:56

University of Kansas Cancer Center Post San Antonio Review

Expert Discussion on Challenging BC Cases: What Treatment Option to Consider for HER2+ De-Novo mBC? What Is the Best 1L Option for T2N0 TNBC Treated With NA AC-T? Does BRCA Status Impact the Choice of Chemo Backbone for IO?

FEATURING Priyanka Sharma, Jennifer Klemp, Heather McArthur, Susan Domchek
  • 170 views
  • February 28, 2021
  • 2
19:16

University of Kansas Cancer Center Post San Antonio Review

BC Predisposition Genes San Antonio Review: Who to Test? Should the Threshold of Detection of Pathogenic Variants Be Mandate or Offer Testing? What Genes to Include?

FEATURING Susan Domchek
  • 90 views
  • February 28, 2021
  • 3
17:29

University of Kansas Cancer Center Post San Antonio Review

SABCS Updates on HR+, HER2- MBC: What Is the Role of HDACi? Does Intrinsic Subtype Predict Benefit to CDK4/6i? Is There a Role for Oral Taxanes? How Effective Are PI3Ki?

FEATURING Sara Tolaney
  • 183 views
  • February 28, 2021
07:53

University of Kansas Cancer Center Post San Antonio Review

SABCS Data on mTNBC: 1L Chemo + IO in PD-L1+ Disease, Sacituzumab Govitecan, 1L AKTi + Chemo

FEATURING Sara Tolaney
  • 218 views
  • February 28, 2021
  • 2
21:41

University of Kansas Cancer Center Post San Antonio Review

Endocrine Resistance in BC: Mechanisms and Treatment Strategies

FEATURING Justin Balko
  • 133 views
  • February 28, 2021
31:02

University of Kansas Cancer Center Post San Antonio Review

Genomic Signatures in Adjuvant Therapy of HR+ EBC: Should We Consider Abemaciclib x2 Years to ET in Very-High Risk Patients? Can Longer CDK4/6i Duration Prevent Late Relapses?

FEATURING Ingrid Mayer
  • 206 views
  • February 28, 2021
  • 1
27:20

University of Kansas Cancer Center Post San Antonio Review

Predictive & Prognostic Biomarkers in Neoadjuvant TNBC: How Valuable Is pCR? Do HRD, DDR & Genomics Have Potential Prognostic Implication? Can SoC AC-T Chemo Backbone Be Reduced? What Is the Importance of TILs?

FEATURING Aditya Bardia
  • 367 views
  • February 23, 2021
  • 5